Background Ocrelizumab, an anti-CD20 humanized monoclonal antibody, reduced disease
progression in pivotal trials of patients with relapsing (OPERA I, OPERA II) and primary …

Background Ocrelizumab is a commonly used anti-CD20 monoclonal antibody with efficacy
in the treatment of both relapsing-remitting (RRMS) and primary progressive (PPMS) …

Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …

B cells play a central role in the pathogenesis of multiple sclerosis (MS): they are involved in
the activation of pro-inflammatory T cells, secretion of pro-inflammatory cytokines and …

Background: The efficacy and safety of ocrelizumab (OCR) in relapsing multiple sclerosis
(RMS) were demonstrated in the 96-week double-blind control period of OPERA I and …

Objective To evaluate the efficacy of ocrelizumab compared with interferon beta-1a (IFNβ-
1a) through pooled analysis of efficacy in OPERA I and OPERA II. Background MS …

Background. Recently, ocrelizumab (Ocrevus®) was approved for the treatment of primary
progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real …

Pivotal trials showed the effectiveness of the monoclonal antibody ocrelizumab in relapsing
and progressive multiple sclerosis (MS). However, data on everyday practice in MS patients …

Methods We included relapsing remitting or active secondary progressive MS patients
treated with Ocrelizumab. Including patients with at least one-year follow-up we assessed …

Background The safety and efficacy of ocrelizumab in primary progressive multiple sclerosis
were shown in the phase 3 ORATORIO trial. In this study, we assessed the effects of …